文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

MUC16：极具潜力的临床靶点。

MUC16: clinical targets with great potential.

机构信息

Zhejiang Cancer Institute, Zhejiang Cancer Hospital, No.1 Banshan East Rd., Gongshu District, Hangzhou, 310022, Zhejiang, China.

Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, Zhejiang, China.

出版信息

Clin Exp Med. 2024 May 17;24(1):101. doi: 10.1007/s10238-024-01365-5.

DOI:10.1007/s10238-024-01365-5
PMID:38758220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11101557/
Abstract

Mucin 16 (MUC16) is a membrane-bound mucin that is abnormally expressed or mutated in a variety of diseases, especially tumors, while being expressed in normal body epithelium. MUC16 and its extracellular components are often important cancer-related biomarkers. Abnormal expression of MUC16 promotes tumor progression through mesenchymal protein, PI3K/AKT pathway, JAK2/STAT3 pathway, ERK/FBW7/c-Myc, and other mechanisms, and plays an important role in the occurrence and development of tumors. In addition, MUC16 also helps tumor immune escape by inhibiting T cells and NK cells. Many drugs and trials targeting MUC16 have been developed, and MUC16 may be a new direction for future treatments. In this paper, the mechanism of action of MUC16 in the development of cancer, especially in the immune escape of tumor, is introduced in detail, indicating the potential of MUC16 in clinical treatment.

摘要

黏蛋白 16（MUC16）是一种膜结合黏蛋白，在多种疾病中异常表达或突变，尤其是肿瘤，而在正常体上皮中表达。MUC16 及其细胞外成分通常是重要的癌症相关生物标志物。MUC16 的异常表达通过间充质蛋白、PI3K/AKT 通路、JAK2/STAT3 通路、ERK/FBW7/c-Myc 等机制促进肿瘤进展，并在肿瘤的发生和发展中发挥重要作用。此外，MUC16 还通过抑制 T 细胞和 NK 细胞来帮助肿瘤免疫逃逸。目前已经开发了许多针对 MUC16 的药物和试验，MUC16 可能是未来治疗的一个新方向。本文详细介绍了 MUC16 在癌症发展中的作用机制，特别是在肿瘤免疫逃逸中的作用机制，表明了 MUC16 在临床治疗中的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/ccc4593cd783/10238_2024_1365_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/82c65726120b/10238_2024_1365_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/91d521c5d6b5/10238_2024_1365_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/f812befb6ae4/10238_2024_1365_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/16751c892bda/10238_2024_1365_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/b2de14284406/10238_2024_1365_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/ccc4593cd783/10238_2024_1365_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/82c65726120b/10238_2024_1365_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/91d521c5d6b5/10238_2024_1365_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/f812befb6ae4/10238_2024_1365_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/16751c892bda/10238_2024_1365_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/b2de14284406/10238_2024_1365_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a45/11101557/ccc4593cd783/10238_2024_1365_Fig6_HTML.jpg

相似文献

[1]
MUC16: clinical targets with great potential.

Clin Exp Med. 2024-5-17

[2]
MUC16/CA125 in cancer: new advances.

Clin Chim Acta. 2025-1-15

[3]
Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.

BMC Cancer. 2019-4-30

[4]
[MUC16: The Novel Target for Tumor Therapy].

Zhongguo Fei Ai Za Zhi. 2022-7-20

[5]
MUC16 facilitates cervical cancer progression via JAK2/STAT3 phosphorylation-mediated cyclooxygenase-2 expression.

Genes Genomics. 2019-11-17

[6]
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Mol Cancer. 2014-5-29

[7]
The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia.

Carcinogenesis. 2021-4-17

[8]
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.

BMC Cancer. 2014-1-21

[9]
Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.

Br J Cancer. 2011-2-15

[10]
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.

Mol Cancer. 2010-1-20

引用本文的文献

[1]
Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.

JCO Precis Oncol. 2025-8

[2]
The multifaceted roles of mucins family in lung cancer: from prognostic biomarkers to promising targets.

Front Immunol. 2025-6-27

[3]
CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.

J Clin Med. 2025-6-11

[4]
Bispecific Antibodies in Solid Tumors: Advances and Challenges.

Int J Mol Sci. 2025-6-18

[5]
Identification and Validation of Key Genes Involved in the Coupling of Mitochondria-Associated Endoplasmic Reticulum Membrane in Hemorrhoidal Disease.

Int J Gen Med. 2025-5-31

[6]
CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights.

Front Immunol. 2025-5-20

[7]
Overlap of Genomic and Transcriptomic Genes Identified in Familial Eosinophilic Esophagitis.

Gastroenterology. 2025-6

[8]
Assessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study.

J Thorac Dis. 2024-11-30

[9]
Hypomethylation-associated ELF3 helps nasopharyngeal carcinoma to escape immune surveillance via MUC16-mediated glycolytic metabolic reprogramming.

Am J Physiol Cell Physiol. 2024-10-1

本文引用的文献

[1]
Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma.

Front Immunol. 2024

[2]
Ligand-based adoptive T cell targeting CA125 in ovarian cancer.

J Transl Med. 2023-9-5

[3]
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.

Cancer Immunol Immunother. 2023-11

[4]
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies.

NPJ Precis Oncol. 2023-8-11

[5]
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects.

PLoS One. 2023

[6]
Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma.

Oncogene. 2022-11

[7]
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.

J Clin Oncol. 2022-12-1

[8]
Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma.

Cancers (Basel). 2022-8-2

[9]
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.

Nat Commun. 2022-8-2

[10]
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.

Oncoimmunology. 2022

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索